Format

Send to

Choose Destination

See 1 citation found by title matching your search:

BMC Cancer. 2018 Jan 25;18(1):97. doi: 10.1186/s12885-018-3994-5.

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.

Author information

1
Medical Oncology Unit, A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.
2
Radiodiagnostic Unit, A.O. Papardo, Messina, Italy.
3
Radiation Oncology Unit, A.O. Papardo, Messina, Italy.
4
Medical Oncology Unit, A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy. vadamo@unime.it.

Abstract

BACKGROUND:

Herein, we report a complete response after whole brain radiotherapy (WBRT) and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and extensive brain and leptomeningeal involvement.

CASE PRESENTATION:

A 46 years old Caucasian woman with HER2-positive MBC and no baseline CNS involvement, started in August 2015 1st line therapy with Pertuzumab-Trastuzumab-Docetaxel, with partial response. However, in April 2016 the patient eventually progressed with emergence of brain and leptomeningeal metastases. Hence, she started in May 2016 2nd line therapy with T-DM1 and concomitant WBRT, with complete response (CR) after 3 courses of therapy, with complete resolution of neurological symptoms and no relevant toxicities. The CR is lasting over 13 months and the patient is out of corticosteroid use.

CONCLUSIONS:

To the best of our knowledge, this is the first case reporting interesting antitumor activity of T-DM1 and concomitant WBRT in both brain and leptomeningeal metastases, with a favorable safety profile and prolonged extracranial disease control. Further prospective studies should confirm these findings.

KEYWORDS:

Brain metastases; HER2-positive; Leptomeningeal metastases; T-DM1; Trastuzumab Emtansine; Whole brain radiotherapy

PMID:
29370839
PMCID:
PMC5784540
DOI:
10.1186/s12885-018-3994-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center